Article Information
History
- July 7, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Camilla Thorlaksen1,2,
- Heidi S. Schultz3,
- Simon K. Gammelgaard4,
- Wim Jiskoot5,
- Nikos S. Hatzakis6,7,
- Flemming S. Nielsen8,
- Helene Solberg9,
- Vito Foderà2,*,
- Christina Bartholdy10 and
- Minna Groenning1,*
- 1Biophysical analysis, Novo Nordisk A/S, Novo Nordisk Park 1, 2760 Måløv, Denmark
- 2Department of Pharmacy and Nanoscience Center, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark
- 3Inflammation, Dragonfly Therapeutics ApS, Baltorpvej 154, 2750 Ballerup, Denmark
- 4MS characterization, Novo Nordisk A/S, Novo Nordisk Park 1, 2760 Måløv, Denmark
- 5Division of BioTherapeutics, Leiden University, Einsteinweg 55, 2300 RA Leiden, Netherlands
- 6Department of Chemistry and Nanoscience Center, University of Copenhagen, Universitetsparken 5, 2100 Copenhagen, Denmark
- 7Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark
- 8Discovery & Development PKPD, Novo Nordisk A/S, Novo Nordisk Park 1, 2760 Måløv, Denmark
- 9Clinical Immunogenicity analysis, Novo Nordisk A/S, Novo Nordisk Park 1, 2760 Måløv, Denmark
- 10In Vivo Biology and Safety, LEO Pharma A/S, Industriparken 55, 2750 Ballerup, Denmark
- ↵*All correspondence should be directed to: mgqj{at}novonordisk.com (MG) and vito.fodera{at}sund.ku.dk (VF)